Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory myeloid or lymphoid neoplasms with an FGFR1 rearrangement.
LAMPGEN ANALYSIS
Why it matters
The action extends an FGFR inhibitor from a solid tumor setting to a rare hematologic neoplasm defined by FGFR1.
What research teams should watch
Confirm the rearrangement and involved lineage and coordinate testing and longitudinal monitoring with hematopathology.
PRIMARY RECORDS